Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Daiichi Sankyo Co Ltd Ord — FY2024 Earnings Presentation
69 slides from Daiichi Sankyo's earnings presentation, Apr 25, 2025
Slide 1: FY2024 Financial Results Presentation
FY2024 Financial Results Presentation DAIICHI SANKYO CO., LTD. Hiroyuki Okuzawa President and CEO April 25, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward-looking statements were determined by Daiichi Sa
Slide 3: Agenda
Agenda 1 FY2024 Financial Results 2 Business Update 3 R&D Update 4 5-Year Business Plan Update 5 FY2025 Forecast 6 Appendix 3
Slide 4: Overview of FY2024 Results
Overview of FY2024 Results (Bn JPY) FY2023 FY2024 YoY Results Results Revenue 1,601.7 1,886.3 +17.8% 284.6 Cost of sales *1 414.8 415.7 1.0 SG&A expenses *1 627.3 724.8 97.5 DXd ADC profit share *2 170.6 226.2 55.6 Other SG&A expenses 456.8 498.6 41.9 R&D expenses *1 364.3 432.9 68.5 Core operating
Slide 5: Revenue
Revenue Increased by 284.6 Bn JPY (Increased by 233.3 Bn JPY excl. forex impact) (Bn JPY) Positive Factors Negative Factors FY2023 Results FY2023 Results 1,601.7 Japan Business Unit Lixiana +17.5 Vaccine business -19.5 Japan Business Tarlige +10.0 Daiichi Sankyo -83.0 (incl. Innovative Pharmaceutica
Slide 6: Core Operating Profit
Core Operating Profit Increased by 117.6 Bn JPY (Increased by 116.8 Bn JPY excl. forex impact) (Bn JPY) Revenue +284.6 incl. forex impact of +51.3 FY2023 Results FY2023 Results 195.3 Cost of Sales -9.8 Improvement in cost of sales ratio by change in product mix Revenue Revenue 284.6 SG&A Expenses +7
Slide 7: Profit Attributable to Owners of the Company
Profit Attributable to Owners of the Company Increased by 95.0 Bn JPY (Bn JPY) Temporary Income/Expenses +2.8 (Profit Increased) FY2023 FY2024 YoY Results Results Temporary Income 27.3*1 22.2*2 -5.1 FY2023 Results FY2023 Results 200.7 Temporary Expenses 10.9 *3 3.1 -7.9 Core Core Operating *1 Lump s
Slide 8: Agenda
Agenda 1 FY2024 Financial Results 2 Business Update 3 R&D Update 4 5-Year Business Plan Update 5 FY2025 Forecast 6 Appendix 8
Slide 9: Progress towards Maximize 3ADCs
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” Progress towards “Identify and build pillars for further growth” Progress towards “Create shared value with stakeholders” 9
Slide 10: ENHERTU Performance
ENHERTU® Performance Global Product Sales FY2024 Product Sales Result 552.8 Bn JPY (YoY +156.9 Bn JPY) FY2025 Forecast 662.1 Bn JPY (YoY +109.3 Bn JPY) Key Growth Factors (YoY YTD Results) and Key Updates + 40% Achieved double-digit growth rate in all regions leading by HER2+ BC 2L and HER2 low BC
Slide 11: DATROWAY Approved and Started Promotion
DATROWAY® (Dato-DXd) Approved and Started Promotion DATROWAY® (anti-TROP2 ADC) approved in Japan, the US and EU - Second product approved on our DXd ADC platform after ENHERTU® Approval acquisition date Japan: December 2024 US: January 2025 EU: April 2025 Indication Unresectable or metasta
Slide 12: Co-development and Co-commercialization for MK-6070
Co-development and Co-commercialization for MK-6070 Added MK-6070*, which is being developed by Merck & Co., Inc., Rahway, NJ, USA (MRK), to the existing global co-development and co-commercialization agreement for 3 DXd ADC products (HER3-DXd, I-DXd, R-DXd) Development Manufacturing Co-develop MK
Slide 13: Progress towards Profit growth for current business and products
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” Progress towards “Identify and build pillars for further growth” Progress towards “Create shared value with stakeholders” 13
Slide 14: Other Regional Initiatives
Other Regional Initiatives Japan EZHARMIA® Anti-Cancer Agent / EZH1 and EZH2 Inhibitor Jun. 2024 Approved for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) Belsomra® Anti-Insomnia Treatment / Dual Orexin Receptor Antagonist Jul. 2024 Decision m
Slide 15: Progress towards Identify and build pillars for further growth
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” Progress towards “Identify and build pillars for further growth” Progress towards “Create shared value with stakeholders” 15
Slide 16: DS-3939 Acquisition of IP Rights for Anti-TA-MUC1 Antibody
DS-3939 Acquisition of Intellectual Property Rights for Anti-TA-MUC1 Antibody In Dec. 2024, acquired the intellectual property rights for gatipotuzumab (anti-TA-MUC1 antibody) from Glycotope* Anti-TA-MUC1** antibody Antibody of our sixth DXd ADC, DS-3939, currently under development by Daiichi S
Slide 17: Progress towards Create shared value with stakeholders
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” Progress towards “Identify and build pillars for further growth” Progress towards “Create shared value with stakeholders” 17
Slide 18: FY2024 Annual Dividend Forecast
FY2024 Annual Dividend Forecast Increase annual dividend forecast per share from 50 JPY (FY2023) to 60 JPY (FY2024) due to strong performance of ENHERTU® and others Annual Dividend per share 331.9 Bn JPY Year-end Dividend 211.6 Bn JPY 60 JPY Interim Dividend Operating Profit 50 JPY 30 120.6 Bn JPY 3
Slide 19: Flexible Acquisition of Own Shares (Results)
Flexible Acquisition of Own Shares (Results) Acquired own shares to strengthen and enhance shareholder returns FY2025 DOE is expected to be over 8.5% Acquisition period: Apr. 26, 2024 – Jan. 9, 2025 Apr. 2024 Aggregate amount of acquisition cost: 200 billion JPY (maximum) Resolution Total
Slide 20: Agenda
Agenda 1 FY2024 Financial Results 2 Business Update 3 R&D Update 4 5-Year Business Plan Update 5 FY2025 Forecast 6 Appendix 20
Slide 21: ASCO 2025 News Flow
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” ASCO 2025 News Flow 21
Slide 22: ENHERTU Pioneered New Classifications of HER2
Achievements in FY2024: ENHERTU® Pioneered New Classifications of HER2 DESTINY-Breast06 Ph3 ENHERTU® demonstrated efficacy in HER2 ultralow as well as HER2 low chemo naïve BC, and is approved in the US and EU PFS for HER2 low (BICR) PFS for ITT（HER2 low and ultralow） (BICR) HR 0.62 HR 0.63 95% CI 0.
Slide 23: ENHERTU Go Earlier in HER2 Positive Breast Cancer
ENHERTU® Go Earlier in HER2 Positive Breast Cancer DESTINY-Breast09 Ph3 Ph3 study evaluating the efficacy and safety of ENHERTU® in mBC either alone or in combination with pertuzumab vs 1L SOC CPS: combined positive score, ET: endocrine therapy, HR: hormone receptor, IHC: immunohistochemistry, mBC:
Slide 24: DESTINY-Breast09 Interim Analysis
ENHERTU® Go Earlier in HER2 Positive Breast Cancer DESTINY-Breast09 Ph3 Interim Analysis ENHERTU®+ pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in PFS as 1L therapy for patients with HER2+ mBC DESTINY-Breast09 Study Design Eligible patients Arm A: EN
Slide 25: ENHERTU Expand Earlier in HER2 Positive Gastric Cancer
ENHERTU® Expand Earlier in HER2 Positive Gastric Cancer Gastric cancer update Improving patient outcomes by expanding into earlier lines and building on the success of ENHERTU® in 2L+ HER2 positive GC HER2 positive gastric cancer 1L 2L 3L (PD-L1 CPS≥1) DESTINY-Gastric05* (Ph3) DESTINY-Gastric02 (Ph2
Slide 26: ENHERTU 1L Treatment for HER2 Overexpressing NSCLC
ENHERTU® 1L Treatment for HER2 Overexpressing NSCLC DESTINY-Lung06 Ph3 Expand into earlier treatment lines by combining with current SOC to maximize patient outcomes for HER2 overexpressing NSCLC DESTINY-Lung06 Study Design Eligible Patients • Locally advanced unresectable or ENHERTU® 5.4mg/kg, q3w
Slide 27: ENHERTU Expansion Beyond DESTINY-PanTumor02
ENHERTU® Expansion Beyond DESTINY-PanTumor02 Opportunities in HER2 Expressing tumors Building on success of Tumor Agnostic indication, opportunities for ENHERTU® continue to expand Expansion of approved countries Apr 2024: Approved in the US HER2 positive (IHC 3+) solid tumors with prior systemic
Slide 28: ENHERTU New Challenge in Gynecological Cancers
ENHERTU® New Challenge in Gynecological Cancers DESTINY-Ovarian01 Ph3 A new Ph3 study for HER2 expressing ovarian cancer 1L maintenance DESTINY-Ovarian01 Study Design Eligible Patients • Histologically confirmed diagnosis of ENHERTU® 5.4mg/kg, q3w epithelial high-grade ovarian, fallopian + bevacizum
Slide 29: DATROWAY Progress in FY2024: Breast Cancer
DATROWAY® Progress in FY2024: Breast Cancer (Dato-DXd) Results based on TROPION-Breast01 Providing new treatment options for HR positive, HER2 negative breast cancer patients DATROWAY® approved in Japan in Dec 2024 and in US in Jan 2025 for HR-positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-)
Slide 30: DATROWAY Progress in FY2024: NSCLC
DATROWAY® Progress in FY2024: NSCLC HER3-DXd HERTHENA-Lung01, HERTHENA-Lung02, TROPION-Lung05 etc. Progressing development for EGFR mutated NSCLC EGFR mutated NSCLC FDA issued CRL for HER3-DXd HERTHENA-Lung01 in June 2024 following inspection of third-party manufacturing facility In Sep 2024, HE
Slide 31: DATROWAY Progress in EGFR mutated NSCLC
DATROWAY® Progress in EGFR mutated NSCLC (Dato-DXd) ORCHARD module10 (ELCC 2025) DATROWAY® in combination with osimertinib demonstrated promising efficacy in EGFR mutated NSCLC progressed after 1L osimertinib Antitumor activity (PFS) ORCHARD (Ph2) EGFR mutated NSCLC progressing on 1L osimertinib m
Slide 32: HER3-DXd Enhance Neoadjuvant Treatment in Breast Cancer
HER3-DXd Enhance Neoadjuvant Treatment in Breast Cancer HERTHENA-Breast03 Ph2 Ph2 signal seeking study for pCR improvement by determining optimal sequence of ADC and chemotherapy in neoadjuvant setting HERTHENA-Breast03 Study Design (Part 2) Eligible Patient Neoadjuvant Cycle 1-4 Neoadjuvant Cycle 5
Slide 33: ASCO 2025 News Flow
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” ASCO 2025 News Flow 33
Slide 34: Major Progress in FY2024: I-DXd and R-DXd
Major Progress in FY2024 I-DXd R-DXd I-DXd and R-DXd demonstrate their significance as 'further growth pillars' supported by the strategic collaboration with MRK* I-DXd R-DXd Steady progress for ES-SCLC Steady progress for ovarian cancer IDeate-Lung01 Ph2 study is proceeding First pivotal Ph
Slide 35: I-DXd: The Third Ph3 Study
I-DXd The Third Ph3 Study IDeate-Prostate01 Ph3 study (monotherapy) New Ph3 study of I-DXd in chemo naive metastatic castration-resistant prostate cancer (mCRPC) IDeate-Prostate01 Study Design Eligible Patients • Metastatic CRPC with ≤2 ARPI treatment I-DXd • Prostate cancer progression while on and
Slide 36: I-DXd: Expanding Target Indication to mCRPC
I-DXd Expanding Target Indication to mCRPC IDeate-Prostate02 Ph1/2 (combination therapy) New Ph1/2 study of I-DXd in chemo naïve metastatic castration-resistant prostate cancer (mCRPC) IDeate-Prostate02 Study Design Eligible Patients docetaxel • Histologically- or cytologically-confirmed adenocarcin
Slide 37: R-DXd: Exploring Possibilities in Gastrointestinal Cancers
R-DXd Exploring Possibilities in Gastrointestinal Cancers REJOICE-GI01 Ph2 Plan to start a signal-seeking study in gastrointestinal cancers in addition to REJOICE-PanTumor01 started in January 2025 REJOICE-GI01 Study Design PDAC Eligible Patients • One of the following cancers: Outcome Measures BTC
Slide 38: Next Wave Progress in FY2024
Next Wave Progress in FY2024 Oncology Specialty Medicine EZHARMIA® (EZH1/2 inhibitor) LIXIANA® (Factor Xa inhibitor) Approval for r/r PTCL in Japan (Jun 2024) Approval for chronic thromboembolic pulmonary Started a Ph1b/2 study for NSCLC 1L in combination with hypertension (CTEPH) in Japan
Slide 39: ASCO 2025 News Flow
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” ASCO 2025 News Flow 39
Slide 40: ASCO Highlights 2025: IR conference call
ASCO Highlights 2025: IR conference call Hiroyuki Okuzawa Ken Takeshita Mark Rutstein President and CEO Head of Global R&D Head of Therapeutic Area Oncology Development Jun 3, 2025 (Tue) 8:00-9:15am JST/ Date and Time Jun 2, 2025 (Mon) 6:00-7:15pm CDT Meeting style Virtual (Zoom) Content will be del
Slide 41: ASCO 2025 News Flow
Progress towards “Maximize 3ADCs” Progress towards “Profit growth for current business and products” ASCO 2025 News Flow 41
Slide 42: FY2025 News Flow
FY2025 News Flow As of Apr 2025 Planned major data disclosures Key data readouts American Society of Clinical Oncology（ASCO, May 30-Jun 3, 2025） DESTINY-Breast11: HER2+ BC, neoadjuvant, Ph3 • FY2025 H1 ENHERTU® DESTINY-Gastric04: HER2+ GC, 2L, Ph3 • Primary results DESTINY-Breast05*: HER2+ BC, Adjuv
Slide 43: Agenda
Agenda 1 FY2024 Financial Results 2 Business Update 3 R&D Update 4 5-Year Business Plan Update 5 FY2025 Forecast 6 Appendix 43
Slide 44: Strategic Pillars for the 5-Year Business Plan (FY2021-FY2025)
Strategic Pillars for the 5-Year Business Plan (FY2021-FY2025) Realize 2025 Goal and Shift to Further Growth FY2025 Revenue: 1.6 Tr JPY (Oncology > 600.0 Bn JPY) ROE > 16% Financial Targets Core Operating Profit* Ratio before R&D Expense: 40％ DOE** > 8% Profit growth for current Identify and
Slide 45: 5-Year Business Plan: Progress in FY2021-FY2024
5-Year Business Plan: Progress in FY2021-FY2024 Maximize 3ADCs Profit growth for current business and products Maximize product value of ENHERTU® Growth of current products Approval of new indication Steady sales expansion of Lixiana® • HER2+ BC 2L, HER2 low BC post-chemo, • Increase product
Slide 46: 5-Year Business Plan: Progress in FY2021-FY2024
5-Year Business Plan: Progress in FY2021-FY2024 Identify and build pillars for further growth Create shared value with stakeholders Emerging growth drivers following 3ADCs Strengthening and enrichment of shareholder returns Progress of development for I-DXd (B7-H3-directed ADC) Shareholder r
Slide 47: Expectation on achieving FY2025 KPIs
Expectation on achieving FY2025 KPIs (as of Apr. 2025) At the time of planning 5YBP As of Apr. 2024 As of Apr. 2025 Revenue 1.6 Tr JPY 2.1 Tr JPY 2.0 Tr JPY Revenue in Oncology > 600.0 Bn JPY > 1.0 Tr JPY 900.0 Bn JPY 40% 40% Core Operating Profit ratio before R&D expense 40% ROE > 16% > 16% > 16% D
Slide 48: Oncology Revenue Forecast
Oncology Revenue Forecast (as of Apr. 2025) FY2025 oncology revenue* is forecasted to be 900 Bn JPY, driven by steady growth of ENHERTU®, despite a decline from the April 2024 forecast due to changes in DATROWAY®’s development strategy Oncology Revenue 900.0 Bn JPY I-DXd、R-DXd HER3-DXd Key drivers o
Slide 49: R&D Expense Forecast
R&D Expense Forecast (as of Apr. 2025) FY2025 R&D expense is forecasted to be 455 Bn JPY based on development plan updates R&D Expense Trend Key drivers of decline vs. Apr 2024 forecast as of Apr. 2024 *1 Clinical development expense as of Apr. 2025 *2 Development plan updated based on strategic
Slide 50: Forecast of FY2025 KPIs
Forecast of FY2025 KPIs (as of Apr. 2025) Revenue Achieve significant revenue/profit growth 2.0 Tr JPY after investment for DXd ADCs, and shift to a new stage for realizing 2030 vision Revenue in Oncology 900.0 Bn JPY 1,886.3 Bn JPY 1,601.7 Bn JPY Revenue 1,278.5 805.0 Bn JPY 745.7 Bn JPY Core O
Slide 51: Daiichi Sankyo will contribute to the enrichment of quality of life around the world
Daiichi Sankyo will contribute to the enrichment of quality of life around the world 51
Slide 52: Agenda
Agenda 1 FY2024 Financial Results 2 Business Update 3 R&D Update 4 5-Year Business Plan Update 5 FY2025 Forecast 6 Appendix 52
Slide 53: FY2025 Forecast
FY2025 Forecast (Bn JPY) FY2024 FY2025 Revenue vs. Forecast : Sales expansion of ENHERTU; Increase in milestone income related to strategic alliance with Results Forecast AstraZeneca and US MRK* Revenue 1,886.3 2,000.0 +113.7 : Decrease due to forex impact * Merck & Co., Inc., Rahway, NJ, USA Cost o
Slide 54: FY2025 Annual Dividend Forecast
FY2025 Annual Dividend Forecast Plan to increase annual dividend to 78 JPY per share for FY2025 (up 18 JPY) due to strong performance of ENHERTU® and others 350.0 Bn JPY 331.9 Bn JPY 78 JPY Annual Dividend per share Year-end Dividend 211.6 Bn JPY 60 JPY Interim Dividend 39 Operating Profit 50 JPY 30
Slide 55: Flexible Acquisition of Own Shares (Resolution)
Flexible Acquisition of Own Shares (Resolution) Established upper limits for acquiring own shares to take flexible actions based on comprehensive consideration such as share price level and other factors FY2025 DOE is expected to be over 8.5% Acquisition period: May. 1, 2025 – Mar. 24, 2026 Up
Slide 56: Agenda
Agenda 1 FY2024 Financial Results 2 Business Update 3 R&D Update 4 5-Year Business Plan Update 5 FY2025 Forecast 6 Appendix 56
Slide 57: Revenue: Business Units (incl. Forex Impact)
Revenue: Business Units (incl. Forex Impact) (Bn JPY) FY2023 FY2024 YoY Results Results Japan Business 518.9 476.9 -42.0 Daiichi Sankyo Healthcare 76.0 86.7 +10.7 Oncolgy Business 334.6 463.8 +129.2 Enhertu 327.4 451.6 +124.2 Turalio 5.3 6.6 +1.3 Vanflyta 1.9 4.5 +2.7 American Regent 203.4 217.2 +13
Slide 58: Revenue: Major Products in Japan
Revenue: Major Products in Japan (Bn JPY) FY2023 FY2024 YoY Results Results Lixiana anticoagulant 115.6 133.0 +17.5 Tarlige pain treatment 45.7 55.6 +10.0 Treatment for osteoporosis/ inhibitor of the progression of Pralia bone erosion associated with rheumatoid arthritis 42.8 42.2 -0.6 Vimpat anti-e
Slide 59: 5DXd ADCs Revenue (incl. Forex Impact)
5DXd ADCs Revenue (incl. Forex Impact) (Unit: Bn JPY) FY2024 FY2025 YoY YoY Results Forecast ENHERTU® 651.4 +202.2 761.5 +110.1 Product Sales 552.8 +156.9 662.1 +109.3 Upfront and Milestone Payments, etc. 98.6 +45.3 99.4 +0.8 DATROWAY® 7.8 +1.4 13.0 +5.2 Product Sales 1.4 +1.4 4.7 +3.2 Upfront and M
Slide 60: 5DXd ADCs Upfront and Milestone Payments
5DXd ADCs Upfront and Milestone Payments (Unit: Bn JPY) FY2024 FY2025 Total Consideration Asset Item YoY YoY Results Forecast (as of Mar 2025) Upfront Payment 10.2 +0.1 10.2 +0.0 149.0 Regulatory Milestones 29.2 +16.9 12.7 -16.5 167.7 ENHERTU® Quid Related Payment 1.2 +0.0 1.2 - 17.2 Sales Milestone
Slide 61: Well-balanced Investment for Growth and Shareholder Returns
Well-balanced Investment for Growth and Shareholder Returns Cash Allocation Increase R&D expense and CAPEX for further growth in future, and increase shareholder returns. Image for cash allocation (Comparison with as of April 2024) R&D Expense Investment for Growth Prioritized investment for DXd-ADC
Slide 62: Major R&D Milestones (ENHERTU)
Major R&D Milestones (ENHERTU®) As of Apr 2025 Target indication FY2024 FY2025 Projecte [phase, study name] H2 H1 H2 • HER2+, adjuvant* [Ph3, DESTINY-Breast05] • TLR anticipated • HR+/HER2 low or HER2 ultralow, chemo naive • Filing accepted（JP/CN) • Regulatory decision [Ph3, DESTINY-Breast06] • Appr
Slide 63: Major R&D Milestones (DATROWAY)
Major R&D Milestones (DATROWAY®) As of Apr 2025 Target indication FY2024 FY2025 Project [phase, study name] H2 H1 H2 • EGFR mutated, previously treated (incl. EGFR • Regulatory decision • Filing accepted (US) directed therapy) [Ph2, TROPION-Lung05*] anticipated (US) NSCLC • w/o AGA, durvalumab combo
Slide 64: Major R&D Milestones (HER3-DXd, I-DXd, R-DXd)
Major R&D Milestones (HER3-DXd, I-DXd, R-DXd) As of Apr 2025 Target indication FY2024 FY2025 Project [phase, study name] H2 H1 H2 • TNBC, HR low and HER2 negative BC HER3-DXd BC neoadjuvant • Study start planned [Ph2, HERTHENA-Breast03] SCLC • 2L+ [Dose optimization, Ph2, IDeate-Lung01] • TLR antici
Slide 65: Major R&D Milestones (Next Wave)
Major R&D Milestones (Next Wave) As of Apr 2025 Target indication FY2024 FY2025 Project [phase, study name] H2 H1 H2 • FLT3-ITD positive AML, 1L VANFLYTA® [Ph3, QuANTUM-First] • Filing accepted (CN) • SCLC, I-DXd combo, 2L+ MK-6070 (gocatamig) [Ph1b/2, MK-6070-002] • Study started DS-2243 • Solid tu
Slide 66: Major R&D Pipeline: 5DXd ADCs ①
Major R&D Pipeline: 5DXd ADCs ① As of Apr 2025 Phase 1 Phase 1/2 Phase 2 (US/EU/Asia) HER2 low BC (JP/US/EU/Asia) NSCLC (US/EU/Asia) HER2+ BC 2L+/1L (JP/US) (JP/US/EU/Asia) (JP/US/EU/Asia) ES-SCLC 2L+ chemo naïve/post chemo DESTINY-Breast07 ESCC, CRPC, squamous NSCLC, SCLC, etc. HER2 expressing soli
Slide 67: Major R&D Pipeline: 5DXd ADCs ②
Major R&D Pipeline: 5DXd ADCs ② As of Apr 2025 Phase 2/3 Phase 3 Regulatory phase (JP/US/EU/Asia) (JP/US/EU/Asia) HER2+ BC (JP) in prep HER2 expressing ovarian cancer (JP/US/EU/Asia) TNBC (PD-1/PD-L1 inhibitor (JP/CN) HR+ and HER2 low or HER2 ultralow platinum-resistant ovarian cancer 2L+ adjuvant*1
Slide 68: Major R&D Pipeline: Next Wave
Major R&D Pipeline: Next Wave As of Apr 2025 Phase 1 Phase 1/2 Phase 2 Phase 3 Regulatory phase DS-1055 (JP/US) DS-3939 (JP/US/EU/Asia) ® EZHARMIA (EU) ® TURALIO (Asia) ® VANFLYTA (CN) Anti-GARP antibody TA-MUC1-directed ADC EZH1/2 inhibitor CSF-1/KIT/FLT3 inhibitor FLT3 inhibitor Solid tumors Solid
Slide 69: Contact address regarding this material
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1125 Email: DaiichiSankyoIR_jp@daiichisankyo.com 69
Daiichi Sankyo Co Ltd Ord — FY2024 Earnings Presentation on 6ix